Jie Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jie Liu has a total of 124 co-authors. Here are the top co-authors by number of shared publications:
- Liang Ouyang
Sichuan University
5 shared publications - Bo Liu
Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China
3 shared publications - Jifa Zhang
Sichuan University
3 shared publications Liang Ouyang
State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, China
3 shared publications- Yongmei Xie
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu, 610041, China
3 shared publications - Cheng-Ming Chiang
Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, United States
2 shared publications
Latest Publications
- 25 April 2026
- Published by Elsevier in Bioorganic Chemistry
- Vol. 177, 109923
ATI-1 mediated disruption of the VCP–UFL1–Beclin1 axis thwarts autophagy initiation to trigger metabolic catastrophe in autophagy-addicted cancers
- 25 April 2026
- Published by Elsevier in Bioorganic Chemistry
- Vol. 177, 109923
ATI-1 mediated disruption of the VCP–UFL1–Beclin1 axis thwarts autophagy initiation to trigger metabolic catastrophe in autophagy-addicted cancers
- Open Access
- 1 January 2025
- Published by Lab Academic Press in Materials Lab
- Vol. 4
Research on α-Mangostin Nanoformulations for Anti-Ovarian Cancer
Ovarian cancer is a type of malignant tumor with a high incidence rate, poor prognosis, and a tendency to relapse. There is a lack of effective therapeutic drugs in the treatment process of ovarian cancer. Alpha-mangostin, an oxyanthenone-type compound, has anti-tumor biological activities. Compared with traditional chemotherapeutic drugs, the advantage of natural source chemotherapeutic drugs lies in lower toxicity, killing tumor cells while reducing damage to normal cells, alleviating the adverse reactions and multi-drug resistance caused by chemotherapy. The nanoformulation was prepared using the thin-film dispersion method, with a particle size of approximately 60 nm. Compared to other drug formulations, its advantage lies in its good biocompatibility. Hydrogels are excellent drug carriers, possessing temperature sensitivity that enables controlled drug release. In this study, the water gel was used as a carrier to wrap the alpha-mangostin nanoparticles to form a nanocomposite hydrogel, and its effects on ovarian cancer cells were evaluated comprehensively, including cell proliferation, apoptosis, and cytotoxicity. Research has confirmed that alpha-mangostin nano-hydrogels can induce apoptosis and inhibit cell proliferation, showing good therapeutic effects on ovarian cancer cells. In summary, alpha-mangostin hydrogel has the potential to become a novel drug formulation for the treatment of ovarian cancer.
- 1 January 2025
- Published by Lab Academic Press in Materials Lab
- Vol. 4
Open AccessResearch on α-Mangostin Nanoformulations for Anti-Ovarian Cancer
Ovarian cancer is a type of malignant tumor with a high incidence rate, poor prognosis, and a tendency to relapse. There is a lack of effective therapeutic drugs in the treatment process of ovarian cancer. Alpha-mangostin, an oxyanthenone-type compound, has anti-tumor biological activities. Compared with traditional chemotherapeutic drugs, the advantage of natural source chemotherapeutic drugs lies in lower toxicity, killing tumor cells while reducing damage to normal cells, alleviating the adverse reactions and multi-drug resistance caused by chemotherapy. The nanoformulation was prepared using the thin-film dispersion method, with a particle size of approximately 60 nm. Compared to other drug formulations, its advantage lies in its good biocompatibility. Hydrogels are excellent drug carriers, possessing temperature sensitivity that enables controlled drug release. In this study, the water gel was used as a carrier to wrap the alpha-mangostin nanoparticles to form a nanocomposite hydrogel, and its effects on ovarian cancer cells were evaluated comprehensively, including cell proliferation, apoptosis, and cytotoxicity. Research has confirmed that alpha-mangostin nano-hydrogels can induce apoptosis and inhibit cell proliferation, showing good therapeutic effects on ovarian cancer cells. In summary, alpha-mangostin hydrogel has the potential to become a novel drug formulation for the treatment of ovarian cancer.
- Open Access
- 20 November 2024
- Published by Georg Thieme Verlag KG in Pharmaceutical Fronts
- Vol. 06 (04) , e336-e354
Boron-Containing Compounds as Antimicrobial Agents to Tackle Drug-Resistant Bacteria
Bacterial infections, especially those caused by drug-resistant bacterial pathogens, are crucial diseases that damage human health. In recent decades, several important boron-containing drugs have been marketed as anticancer agents or anti-infective adjuvants. Among them, vaborbactam revitalizes the antibacterial effects of meropenem against bacteria by inhibiting β-lactamases, opening a new field for addressing bacterial resistance. In this article, the chemical features of boron atoms and the typical antibacterial agents and adjuvants of boron-containing compounds are reviewed. In this work, boron-containing agents are classified into four categories according to their action mechanisms: β-lactamase inhibitors, leucyl-tRNA synthetase inhibitors, LexA self-cleavage inhibitors, and NorA efflux pump inhibitors. This review provides actionable insights for addressing the increasingly severe drug-resistant infections of bacterial pathogens. # These authors contributed equally to this work. Received: 28 March 2024 Accepted: 08 October 2024 Article published online: 20 November 2024 © 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 20 November 2024
- Published by Georg Thieme Verlag KG in Pharmaceutical Fronts
- Vol. 06 (04) , e336-e354
Open AccessBoron-Containing Compounds as Antimicrobial Agents to Tackle Drug-Resistant Bacteria
Bacterial infections, especially those caused by drug-resistant bacterial pathogens, are crucial diseases that damage human health. In recent decades, several important boron-containing drugs have been marketed as anticancer agents or anti-infective adjuvants. Among them, vaborbactam revitalizes the antibacterial effects of meropenem against bacteria by inhibiting β-lactamases, opening a new field for addressing bacterial resistance. In this article, the chemical features of boron atoms and the typical antibacterial agents and adjuvants of boron-containing compounds are reviewed. In this work, boron-containing agents are classified into four categories according to their action mechanisms: β-lactamase inhibitors, leucyl-tRNA synthetase inhibitors, LexA self-cleavage inhibitors, and NorA efflux pump inhibitors. This review provides actionable insights for addressing the increasingly severe drug-resistant infections of bacterial pathogens. # These authors contributed equally to this work. Received: 28 March 2024 Accepted: 08 October 2024 Article published online: 20 November 2024 © 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 2 September 2024
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 278, 116804
An update on small molecule compounds targeting synthetic lethality for cancer therapy
- 2 September 2024
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 278, 116804
An update on small molecule compounds targeting synthetic lethality for cancer therapy
- 23 February 2024
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 268, 116240
Fragment growth-based discovery of novel TNIK inhibitors for the treatment of colorectal cancer
- 23 February 2024
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 268, 116240
Fragment growth-based discovery of novel TNIK inhibitors for the treatment of colorectal cancer
- 10 May 2023
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 256, 115475
Small-molecule LRRK2 inhibitors for PD therapy: Current achievements and future perspectives
- 10 May 2023
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 256, 115475
Small-molecule LRRK2 inhibitors for PD therapy: Current achievements and future perspectives
- 11 October 2021
- Published by Wiley in Medicinal Research Reviews
- Vol. 42 (2) , 710-743
Dual‐target inhibitors of bromodomain and extra‐terminal proteins in cancer: A review from medicinal chemistry perspectives
Bromodomain‐containing protein 4 (BRD4), as the most studied member of the bromodomain and extra‐terminal (BET) family, is a chromatin reader protein interpreting epigenetic codes through binding to acetylated histones and non‐histone proteins, thereby regulating diverse cellular processes including cell cycle, cell differentiation, and cell proliferation. As a promising drug target, BRD4 function is closely related to cancer, inflammation, cardiovascular disease, and liver fibrosis. Currently, clinical resistance to BET inhibitors has limited their applications but synergistic antitumor effects have been observed when used in combination with other tumor inhibitors targeting additional cellular components such as PLK1, HDAC, CDK, and PARP1. Therefore, designing dual‐target inhibitors of BET bromodomains is a rational strategy in cancer treatment to increase potency and reduce drug resistance. This review summarizes the protein structures and biological functions of BRD4 and discusses recent advances of dual BET inhibitors from a medicinal chemistry perspective. We also discuss the current design and discovery strategies for dual BET inhibitors, providing insight into potential discovery of additional dual‐target BET inhibitors.
- 11 October 2021
- Published by Wiley in Medicinal Research Reviews
- Vol. 42 (2) , 710-743
Dual‐target inhibitors of bromodomain and extra‐terminal proteins in cancer: A review from medicinal chemistry perspectives
Bromodomain‐containing protein 4 (BRD4), as the most studied member of the bromodomain and extra‐terminal (BET) family, is a chromatin reader protein interpreting epigenetic codes through binding to acetylated histones and non‐histone proteins, thereby regulating diverse cellular processes including cell cycle, cell differentiation, and cell proliferation. As a promising drug target, BRD4 function is closely related to cancer, inflammation, cardiovascular disease, and liver fibrosis. Currently, clinical resistance to BET inhibitors has limited their applications but synergistic antitumor effects have been observed when used in combination with other tumor inhibitors targeting additional cellular components such as PLK1, HDAC, CDK, and PARP1. Therefore, designing dual‐target inhibitors of BET bromodomains is a rational strategy in cancer treatment to increase potency and reduce drug resistance. This review summarizes the protein structures and biological functions of BRD4 and discusses recent advances of dual BET inhibitors from a medicinal chemistry perspective. We also discuss the current design and discovery strategies for dual BET inhibitors, providing insight into potential discovery of additional dual‐target BET inhibitors.
- 22 February 2021
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 64 (5) , 2419-2435
Targeting Bromodomain and Extraterminal Proteins for Drug Discovery: From Current Progress to Technological Development
Bromodomain and extraterminal (BET) proteins bind acetylated lysine residues in histones and nonhistone proteins via tandem bromodomains and regulate chromatin dynamics, cellular processes, and disease procession. Thus targeting BET proteins is a promising strategy for treating various diseases, especially malignant tumors and chronic inflammation. Many pan-BET small-molecule inhibitors have been described, and some of them are in clinical evaluation. Nevertheless, the limited clinical efficacy of the current BET inhibitors is also evident and has inspired the development of new technologies to improve their clinical outcomes and minimize unwanted side effects. In this Review, we summarize the latest protein characteristics and biological functions of BRD4 as an example of BET proteins, analyze the clinical development status and preclinical resistance mechanisms, and discuss recent advances in BRD4-selective inhibitors, dual-target BET inhibitors, proteolysis targeting chimera degraders, and protein–protein interaction inhibitors.
- 22 February 2021
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 64 (5) , 2419-2435
Targeting Bromodomain and Extraterminal Proteins for Drug Discovery: From Current Progress to Technological Development
Bromodomain and extraterminal (BET) proteins bind acetylated lysine residues in histones and nonhistone proteins via tandem bromodomains and regulate chromatin dynamics, cellular processes, and disease procession. Thus targeting BET proteins is a promising strategy for treating various diseases, especially malignant tumors and chronic inflammation. Many pan-BET small-molecule inhibitors have been described, and some of them are in clinical evaluation. Nevertheless, the limited clinical efficacy of the current BET inhibitors is also evident and has inspired the development of new technologies to improve their clinical outcomes and minimize unwanted side effects. In this Review, we summarize the latest protein characteristics and biological functions of BRD4 as an example of BET proteins, analyze the clinical development status and preclinical resistance mechanisms, and discuss recent advances in BRD4-selective inhibitors, dual-target BET inhibitors, proteolysis targeting chimera degraders, and protein–protein interaction inhibitors.
- 1 January 2021
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 209, 112917
Targeting Atg4B for cancer therapy: Chemical mediators
- 1 January 2021
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 209, 112917
Targeting Atg4B for cancer therapy: Chemical mediators
- Open Access
- 1 January 2021
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 11 (1) , 156-180
Design, synthesis, and biological evaluation of quinazolin-4(3H)-one derivatives co-targeting poly(ADP-ribose) polymerase-1 and bromodomain containing protein 4 for breast cancer therapy
- 1 January 2021
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 11 (1) , 156-180
Open AccessDesign, synthesis, and biological evaluation of quinazolin-4(3H)-one derivatives co-targeting poly(ADP-ribose) polymerase-1 and bromodomain containing protein 4 for breast cancer therapy